Dacomitinib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 410 publications

Salvage dacomitinib plus intraventricular pemetrexed for leptomeningeal metastasis after failure of third‑generation EGFR‑TKIs in EGFR‑mutant NSCLC: an ambispective cohort study.

Salvage dacomitinib plus intraventricular pemetrexed for leptomeningeal metastasis after failure of third‑generation EGFR‑TKIs in EGFR‑mutant NSCLC: an ambispective cohort study.

Journal: Journal of neuro-oncology

Published: February 13, 2026

Beyond EGFR inhibition in head and neck squamous cell carcinoma: Overcoming resistance mechanisms and novel therapeutic frontiers.

Beyond EGFR inhibition in head and neck squamous cell carcinoma: Overcoming resistance mechanisms and novel therapeutic frontiers.

Journal: Critical reviews in oncology/hematology

Published: December 07, 2025

From Gefitinib to Amivantamab: Progress and Perspectives of Therapies Targeting the Epidermal Growth Factor Receptor in the Era of Precision Oncology.

From Gefitinib to Amivantamab: Progress and Perspectives of Therapies Targeting the Epidermal Growth Factor Receptor in the Era of Precision Oncology.

Journal: Journal of cancer prevention

Published: December 01, 2025

Multimodal investigation of dacomitinib-calf thymus DNA binding interaction: insights from spectroscopy, thermodynamics, and in-silico studies.

Multimodal investigation of dacomitinib-calf thymus DNA binding interaction: insights from spectroscopy, thermodynamics, and in-silico studies.

Journal: RSC advances

Published: November 29, 2025

Medicinal chemistry perspective on quinazoline derivatives: Sustainable synthetic routes, anticancer evaluation, and SAR analysis.

Medicinal chemistry perspective on quinazoline derivatives: Sustainable synthetic routes, anticancer evaluation, and SAR analysis.

Journal: European journal of medicinal chemistry

Published: October 12, 2025

Dacomitinib as a First-Line Therapy for Advanced EGFR-Mutated Non-Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study.

Dacomitinib as a First-Line Therapy for Advanced EGFR-Mutated Non-Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study.

Journal: Cancer medicine

Published: October 11, 2025

Update on the Treatment of Non-Small Cell Lung Carcinoma (NSCLC).

Update on the Treatment of Non-Small Cell Lung Carcinoma (NSCLC).

Journal: Journal of clinical medicine

Published: September 07, 2025

Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study.

Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 20, 2025

Effect of Tongdu Jieyu acupuncture on hippocampal neuronal damage in post-stroke depression rats based on the NRG1/ErbB4 pathway

Effect of Tongdu Jieyu acupuncture on hippocampal neuronal damage in post-stroke depression rats based on the NRG1/ErbB4 pathway

Journal: Zhongguo zhen jiu = Chinese acupuncture & moxibustion

Published: August 19, 2025

Hepatotoxicity and efficacy associated with first- and new-generation EGFR-TKIs in patients with NSCLC: a systematic review and meta-analysis.

Hepatotoxicity and efficacy associated with first- and new-generation EGFR-TKIs in patients with NSCLC: a systematic review and meta-analysis.

Journal: BMC cancer

Published: July 10, 2025

Sequential tyrosine kinase inhibitor therapy for EGFR L747P-mutated lung adenocarcinoma in a renal transplant recipient: a 24-month case report.

Sequential tyrosine kinase inhibitor therapy for EGFR L747P-mutated lung adenocarcinoma in a renal transplant recipient: a 24-month case report.

Journal: Frontiers in medicine

Published: July 10, 2025

Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies.

Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies.

Journal: Molecular oncology

Published: July 04, 2025

Showing 1-12 of 410

Last Updated: 04/28/2026